Trial · NCT02136420

Countermeasures to Reduce Sensorimotor Impairment and Space Motion Sickness Resulting From Altered Gravity Levels

NCT02136420, Phase 4, Completed; results first posted 2018-01-08

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Countermeasures to Reduce Sensorimotor Impairment and Space Motion Sickness Resulting From Altered Gravity Levels. Trials, record NCT02136420. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02136420

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Countermeasures to Reduce Sensorimotor Impairment and Space Motion Sickness Resulting From Altered Gravity Levels
NCT number: NCT02136420
Status: Completed
Phases: Phase 4
Enrollment: 30 participants, actual
Conditions: Vestibular
Interventions: Promethazine, Hyper gravity training, Placebo, No hypergravity training
First posted: 2014-05-13
Last updated: 2018-01-08
Results first posted: 2018-01-08

Source ClinicalTrials.gov

Registered outcomes5

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Percent Change in Roll Tilt Perception After Exposure to Hypogravity	1 session	Note that this applies to arms 1-4 only. Subjects sat on a chair on a moving platform on top of a centrifuge that created an artificial gravity environment. Subjects were repeatedly roll tilted to angles between 11 and 19 degrees, and then reported their perceived tilt angle using a subjective visual vertical task. They did this while experiencing centripetal acceleration equivalent to Earth gravity (1 Gz), and then hypogravity (0.5 Gz). We hypothesized that, after entering hypogravity, subjects would tend to underestimate their tilt angle. We calculated the percent change in their perception of tilt between 1 Gz and 0.5 Gz.
Primary	Yaw Perceptual Motion Threshold	2 sessions separated by at least four days; measurements made 2 hrs after ingestion of medication	This is a perceptual self-motion threshold that measures the precision of the vestibular system. It is analogous to an audiogram, but for motion. Subjects sat on a motorized platform which repeatedly provided them with small motions to the left or right. After each motion subjects report whether they perceived a motion to the left or right. Based on subject responses, a psychometric curve fit is performed that determines the threshold (the standard deviation of the underlying cumulative Gaussian). Yaw rotation means rotations about an axis that is perpendicular to gravity. This outcome measure applies only to arm 5 subjects.
Primary	Roll Perceptual Motion Threshold	2 sessions separated by at least four days; measurements made 2 hrs after ingestion of medication	This is a perceptual self-motion threshold that measures the precision of the vestibular system. It is analogous to an audiogram, but for motion. Subjects sat on a motorized platform which repeatedly provided them with small motions to the left or right. After each motion subjects report whether they perceived a motion to the left or right. Based on subject responses, a psychometric curve fit is performed that determines the threshold (the standard deviation of the underlying cumulative Gaussian). Roll tilt means rotations about an axis that is Earth-horizontal. This outcome measure applies only to arm 5 subjects.
Primary	Interaural Perceptual Motion Threshold	2 sessions separated by at least four days; measurements made 2 hrs after ingestion of medication	This is a perceptual self-motion threshold that measures the precision of the vestibular system. It is analogous to an audiogram, but for motion. Subjects sat on a motorized platform which repeatedly provided them with small motions to the left or right. After each motion subjects report whether they perceived a motion to the left or right. Based on subject responses, a psychometric curve fit is performed that determines the threshold (the standard deviation of the underlying cumulative Gaussian). Interaural translation refers to translations in the horizontal plane to the subject's left or right. This outcome measure applies only to arm 5 subjects.
Primary	Percent Change in Manual Control Performance After Exposure to Hypogravity	1 session	Note that this applies to arms 6-9 only. Subjects sat on a chair on a moving platform on top of a centrifuge that created an artificial gravity environment. Subjects completed a manual control task in which their charge was randomly perturbed in roll tilt, and they used a joystick to attempt to keep themselves aligned with upright, while in the dark. They did this while experiencing centripetal acceleration equivalent to Earth gravity (1 Gz), and then hypogravity (0.5 Gz). We calculated their performance by calculating the standard deviation of chair position across time, with a smaller number indicating better performance. Then we calculated the percent change in their performance between 1 Gz and 0.5 Gz.

Source ClinicalTrials.gov

Outcomes5

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Units	Measured as
PRIMARY	Percent Change in Roll Tilt Perception After Exposure to Hypogravity	1 session	percentage change	MEAN
PRIMARY	Yaw Perceptual Motion Threshold	2 sessions separated by at least four days; measurements made 2 hrs after ingestion of medication	deg per sec	GEOMETRIC_MEAN
PRIMARY	Roll Perceptual Motion Threshold	2 sessions separated by at least four days; measurements made 2 hrs after ingestion of medication	deg per sec	GEOMETRIC_MEAN
PRIMARY	Interaural Perceptual Motion Threshold	2 sessions separated by at least four days; measurements made 2 hrs after ingestion of medication	cm per sec	GEOMETRIC_MEAN
PRIMARY	Percent Change in Manual Control Performance After Exposure to Hypogravity	1 session	percentage change	MEAN

Source ClinicalTrials.gov

Results by group14

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Percent Change in Roll Tilt Perception After Exposure to Hypogravity	Training, Placebo		27.0	Full Range 7.4 to 57.1	percentage change
Yaw Perceptual Motion Threshold	Perceptual Thresholds,Drug Then Placebo	Placebo	.83	Standard Deviation .25	deg per sec
Yaw Perceptual Motion Threshold	Perceptual Thresholds,Placebo Then Drug	Placebo	.92	Standard Deviation .29	deg per sec
Yaw Perceptual Motion Threshold	Perceptual Thresholds,Drug Then Placebo	Promethazine	.86	Standard Deviation .19	deg per sec
Yaw Perceptual Motion Threshold	Perceptual Thresholds,Placebo Then Drug	Promethazine	1.06	Standard Deviation .26	deg per sec
Roll Perceptual Motion Threshold	Perceptual Thresholds,Drug Then Placebo	Placebo	.27	Standard Deviation .15	deg per sec
Roll Perceptual Motion Threshold	Perceptual Thresholds,Placebo Then Drug	Placebo	.32	Standard Deviation .12	deg per sec
Roll Perceptual Motion Threshold	Perceptual Thresholds,Drug Then Placebo	Promethazine	.39	Standard Deviation .20	deg per sec
Roll Perceptual Motion Threshold	Perceptual Thresholds,Placebo Then Drug	Promethazine	.39	Standard Deviation .13	deg per sec
Interaural Perceptual Motion Threshold	Perceptual Thresholds,Drug Then Placebo	Placebo	.57	Standard Deviation .17	cm per sec

1 to 10 of 14Source ClinicalTrials.gov

See all 14 results by group

Participant flow30

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Tilt Perception, Training, Placebo	10
Overall Study	STARTED	Tilt Perception, No Training, Placebo	0
Overall Study	STARTED	Tilt Perception, Training, Promethazine	0
Overall Study	STARTED	Tilt Perception,No Training,Promethazine	0
Overall Study	STARTED	Manual Control, Training, Placebo	10
Overall Study	STARTED	Manual Control, No Training, Placebo	0
Overall Study	STARTED	Manual Control, Training, Promethazine	0
Overall Study	STARTED	Manual Control,No Training,Promethazine	0
Overall Study	STARTED	Perceptual Thresholds,Drug Then Placebo	5
Overall Study	STARTED	Perceptual Thresholds,Placebo Then Drug	5

1 to 10 of 30Source ClinicalTrials.gov

See all 30 participant flow

Adverse events0

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

None in this release.

Adverse event totals30

The totals the trial posted for each group.

Total	Group	At risk
Total, all-cause mortality	Tilt Perception, Training, Placebo	10
Total, all-cause mortality	Tilt Perception, No Training, Placebo	0
Total, all-cause mortality	Tilt Perception, Training, Promethazine	0
Total, all-cause mortality	Tilt Perception, No Training, Promethazine	0
Total, all-cause mortality	Perceptual Threshold Testing: Promethazine	10
Total, all-cause mortality	Perceptual Motion Threshold Testing: Placebo	10
Total, all-cause mortality	Manual Control, Training, Placebo	10
Total, all-cause mortality	Manual Control, No Training, Placebo	0
Total, all-cause mortality	Manual Control, Training, Promethazine	0
Total, all-cause mortality	Manual Control, No Training, Promethazine	0

1 to 10 of 30Source ClinicalTrials.gov

See all 30 adverse event totals

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
28439720	RESULT

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT02136420

GET https://conductscience.org/api/trials/v1/NCT02136420/flow?page=2

API reference For AI assistants